These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 19021634)

  • 1. Estrogen receptor status in CHEK2-positive breast cancers: implications for chemoprevention.
    Cybulski C; Huzarski T; Byrski T; Gronwald J; Debniak T; Jakubowska A; Górski B; Wokołorczyk D; Masojć B; Narod SA; Lubiński J
    Clin Genet; 2009 Jan; 75(1):72-8. PubMed ID: 19021634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CHEK2-positive breast cancers in young Polish women.
    Cybulski C; Górski B; Huzarski T; Byrski T; Gronwald J; Debniak T; Wokolorczyk D; Jakubowska A; Kowalska E; Oszurek O; Narod SA; Lubinski J
    Clin Cancer Res; 2006 Aug; 12(16):4832-5. PubMed ID: 16914568
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A deletion in CHEK2 of 5,395 bp predisposes to breast cancer in Poland.
    Cybulski C; Wokołorczyk D; Huzarski T; Byrski T; Gronwald J; Górski B; Debniak T; Masojć B; Jakubowska A; van de Wetering T; Narod SA; Lubiński J
    Breast Cancer Res Treat; 2007 Mar; 102(1):119-22. PubMed ID: 16897426
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of breast cancer in women with a CHEK2 mutation with and without a family history of breast cancer.
    Cybulski C; Wokołorczyk D; Jakubowska A; Huzarski T; Byrski T; Gronwald J; Masojć B; Deebniak T; Górski B; Blecharz P; Narod SA; Lubiński J
    J Clin Oncol; 2011 Oct; 29(28):3747-52. PubMed ID: 21876083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of CHEK2 missense variant I157T on the risk of breast cancer in carriers of other CHEK2 or BRCA1 mutations.
    Cybulski C; Górski B; Huzarski T; Byrski T; Gronwald J; Debniak T; Wokolorczyk D; Jakubowska A; Serrano-Fernández P; Dork T; Narod SA; Lubinski J
    J Med Genet; 2009 Feb; 46(2):132-5. PubMed ID: 18930998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Excess breast cancer risk in first degree relatives of CHEK2∗1100delC positive familial breast cancer cases.
    Adank MA; Verhoef S; Oldenburg RA; Schmidt MK; Hooning MJ; Martens JW; Broeks A; Rookus M; Waisfisz Q; Witte BI; Jonker MA; Meijers-Heijboer H
    Eur J Cancer; 2013 May; 49(8):1993-9. PubMed ID: 23415889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumour characteristics and prognosis of breast cancer patients carrying the germline CHEK2*1100delC variant.
    de Bock GH; Schutte M; Krol-Warmerdam EM; Seynaeve C; Blom J; Brekelmans CT; Meijers-Heijboer H; van Asperen CJ; Cornelisse CJ; Devilee P; Tollenaar RA; Klijn JG
    J Med Genet; 2004 Oct; 41(10):731-5. PubMed ID: 15466005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Breast cancer in patients carrying a germ-line CHEK2 mutation: Outcome after breast conserving surgery and adjuvant radiotherapy.
    Meyer A; Dörk T; Sohn C; Karstens JH; Bremer M
    Radiother Oncol; 2007 Mar; 82(3):349-53. PubMed ID: 17250914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls.
    Weischer M; Bojesen SE; Ellervik C; Tybjaerg-Hansen A; Nordestgaard BG
    J Clin Oncol; 2008 Feb; 26(4):542-8. PubMed ID: 18172190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic interaction of variants in CHEK2 and BRCA2 on breast cancer risk.
    Serrano-Fernández P; Debniak T; Górski B; Bogdanova N; Dörk T; Cybulski C; Huzarski T; Byrski T; Gronwald J; Wokołorczyk D; Narod SA; Lubiński J
    Breast Cancer Res Treat; 2009 Sep; 117(1):161-5. PubMed ID: 19030985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Different CHEK2 germline mutations are associated with distinct immunophenotypic molecular subtypes of breast cancer.
    Domagala P; Wokolorczyk D; Cybulski C; Huzarski T; Lubinski J; Domagala W
    Breast Cancer Res Treat; 2012 Apr; 132(3):937-45. PubMed ID: 21701879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Breast cancer survival and tumor characteristics in premenopausal women carrying the CHEK2*1100delC germline mutation.
    Schmidt MK; Tollenaar RA; de Kemp SR; Broeks A; Cornelisse CJ; Smit VT; Peterse JL; van Leeuwen FE; Van't Veer LJ
    J Clin Oncol; 2007 Jan; 25(1):64-9. PubMed ID: 17132695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased risk of breast cancer associated with CHEK2*1100delC.
    Weischer M; Bojesen SE; Tybjaerg-Hansen A; Axelsson CK; Nordestgaard BG
    J Clin Oncol; 2007 Jan; 25(1):57-63. PubMed ID: 16880452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Breast cancer predisposing alleles in Poland.
    Górski B; Cybulski C; Huzarski T; Byrski T; Gronwald J; Jakubowska A; Stawicka M; Gozdecka-Grodecka S; Szwiec M; Urbański K; Mituś J; Marczyk E; Dziuba J; Wandzel P; Surdyka D; Haus O; Janiszewska H; Debniak T; Tołoczko-Grabarek A; Medrek K; Masojć B; Mierzejewski M; Kowalska E; Narod SA; Lubiński J
    Breast Cancer Res Treat; 2005 Jul; 92(1):19-24. PubMed ID: 15980987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Absence of CHEK2*1100delC mutation in families with hereditary breast cancer in North America.
    Iniesta MD; Gorin MA; Chien LC; Thomas SM; Milliron KJ; Douglas JA; Merajver SD
    Cancer Genet Cytogenet; 2010 Oct; 202(2):136-40. PubMed ID: 20875877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CHEK2*1100delC homozygosity is associated with a high breast cancer risk in women.
    Adank MA; Jonker MA; Kluijt I; van Mil SE; Oldenburg RA; Mooi WJ; Hogervorst FB; van den Ouweland AM; Gille JJ; Schmidt MK; van der Vaart AW; Meijers-Heijboer H; Waisfisz Q
    J Med Genet; 2011 Dec; 48(12):860-3. PubMed ID: 22058428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathology of breast cancer in women with constitutional CHEK2 mutations.
    Huzarski T; Cybulski C; Domagała W; Gronwald J; Byrski T; Szwiec M; Woyke S; Narod SA; Lubiński J
    Breast Cancer Res Treat; 2005 Mar; 90(2):187-9. PubMed ID: 15803365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Germline CHEK2 mutations in Jewish Ashkenazi women at high risk for breast cancer.
    Laitman Y; Kaufman B; Lahad EL; Papa MZ; Friedman E
    Isr Med Assoc J; 2007 Nov; 9(11):791-6. PubMed ID: 18085035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tamoxifen as chemoprevention in BRCA1 and BRCA2 mutation carriers with breast cancer: a pilot survey of physicians.
    Peshkin BN; Isaacs C; Finch C; Kent S; Schwartz MD
    J Clin Oncol; 2003 Dec; 21(23):4322-8. PubMed ID: 14645421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The CHEK2*1100delC variant acts as a breast cancer risk modifier in non-BRCA1/BRCA2 multiple-case families.
    Oldenburg RA; Kroeze-Jansema K; Kraan J; Morreau H; Klijn JG; Hoogerbrugge N; Ligtenberg MJ; van Asperen CJ; Vasen HF; Meijers C; Meijers-Heijboer H; de Bock TH; Cornelisse CJ; Devilee P
    Cancer Res; 2003 Dec; 63(23):8153-7. PubMed ID: 14678969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.